Erica Melick, APRN
Clinical Nurse Specialist · Oklahoma City, OKNPI 1255903662
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,383 of the $4,849 with a category attached, or 69.8%. 18 manufacturers reported payments, led by Edwards Lifesciences at 44.4% of the total. 2025 is the largest year on record at $2,566, more than ten times the $209 reported in 2021. Among clinical nurse specialist clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 97 payments — averaging $49.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Abiomed$398
- Medtronic$390
- E.r. Squibb & Sons, L.L.C.$363
- Alnylam Pharmaceuticals Inc.$289
- AstraZeneca$275
- plus $983 from 12 others
What the payments were for
- Consulting fees$2505%
- Travel & lodging$1,21525%
- Food & beverage$3,38370%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 19 | $2,151 |
| Abiomed | 4 | $398 |
| Medtronic | 5 | $390 |
| E.r. Squibb & Sons, L.L.C. | 10 | $363 |
| Alnylam Pharmaceuticals Inc. | 6 | $289 |
| AstraZeneca | 13 | $275 |
| Shockwave Medical, Inc | 11 | $226 |
| Amgen | 5 | $187 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $164 |
| Esperion Therapeutics, Inc. | 1 | $85 |
| Novartis | 4 | $80 |
| Kowa Pharmaceuticals America, Inc. | 6 | $79 |
| Amarin Pharma, Inc. | 3 | $51 |
| Pfizer | 2 | $35 |
| Boehringer Ingelheim | 1 | $23 |
| Irhythm Technologies, Inc. | 1 | $20 |
| Cashflow Solutions, LLC | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPIEN 3 Ultra RESILIA$485
- Impella$286
- Edwards SAPIEN 3 Transcatheter Heart Valve$250
- AMVUTTRA$247
- PASCAL$175
- CAMZYOS$133
- Repatha$121
- SelectSecure$114
- MyCareLink$114
- AURORA EV-ICD MRI SURESCAN$106
How this compares
$4,849 in reported general payments places this provider in the 90th percentile of 56 clinical nurse specialist providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 117 | $90,507 |
| FarxigaDapagliflozin Propanediol | 57 | $45,375 |
| EliquisApixaban | 37 | $39,757 |
| JardianceEmpagliflozin | 40 | $37,196 |
| Metoprolol Succinate | 129 | $1,304 |
| Carvedilol | 90 | $673 |
| Atorvastatin Calcium | 92 | $538 |
| Losartan Potassium | 52 | $498 |
| Amlodipine Besylate | 51 | $434 |
| Nitroglycerin | 11 | $316 |
| Spironolactone | 88 | $298 |
| Torsemide | 16 | $267 |
| Furosemide | 61 | $253 |
| Lisinopril | 59 | $200 |
| Ezetimibe | 13 | $194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $80 | $90,507117 claims |
| AstraZenecaFarxiga | $275 | $45,37557 claims |
| PfizerEliquis | $35 | $39,75737 claims |
| Boehringer IngelheimJardiance | $23 | $37,19640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 56 clinical nurse specialist providers in Oklahoma.
Other clinical nurse specialist in Oklahoma City
- Kelly Lang-SheppardOklahoma City$5K
- Cheryl WestOklahoma City$4K
- April MerrillOklahoma City$2K
- Danielle ZacharyOklahoma City$2K
- Heather GrahamOklahoma City$2K
- Amy EberleOklahoma City$1K
- Robin MartinOklahoma City$1K
- Michelle PopeOklahoma City$1K
- Linda PitchfordOklahoma City$929
- Tara SukutOklahoma City$852
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.